SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults
  Author: Mateen Dalal

The company is looking forward to enrolling patients with desmoid tumors to confirm the clinical benefits of nirogacestat SpringWorks Therapeutics, a clinical-stage...

Read More >>
Cook Medical, Ambu A/S to jointly address endoscope-related infections
  Author: Pankaj Singh

The two firms will bring forth single-use endoscopes to patients undergoing ERCP procedures to reduce the risk associated with serious cross-contaminations. Medical...

Read More >>
Exelixis & Iconic Therapeutics ink exclusive license and option deal
  Author: Mateen Dalal

The exclusive license & option agreement has been signed for a new Antibody-Drug conjugate program.   The program, named ICON-2, sp...

Read More >>
Unichem Lab gets tentative nod from USFDA for hydrochloride medicines
  Author: Mateen Dalal

These tablets are indicated for nasal decongestant and antihistamine Unichem may produce and market the generic drug products after approval ...

Read More >>
Roche, Bio-Techne extend collaboration over mRNA ISH tissue analysis
  Author: Mateen Dalal

Roche’s new detection kits have more translucent dyes which are suited for mRNA ISH co-localization studies Swiss healthcare company Roche has recently announ...

Read More >>
Esperion confirms FDA acceptance of two NDAs for regulatory review
  Author: Mateen Dalal

The NDAs are for oral therapies developed as medication for patients with raised LDL-C who require additional LDL-C lowering Esperion has recently announced that th...

Read More >>
Innovation Pharma obtains FDA guidance for Brilacidin Phase 3 program
  Author: Mateen Dalal

Brilacidin oral rinse is supposedly being developed as part of FDA Fast Track designation for Oral Mucositis Reports confirm that Innovation Pharmaceuticals, a clin...

Read More >>
Cerevance successfully completes Phase 1 clinical trial of CVN424
  Author: Pankaj Singh

Clinical stage biopharmaceutical company Cerevance has reportedly completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, oral drug in development for treating Parkinson’s disease. The...

Read More >>
EU CHMP recommends LYNPARZA as first-line treatment for ovarian cancer
  Author: Pankaj Singh

AstraZeneca & Merck’s LYNPARZA has reportedly received a positive opinion from the EMA’s (European Medicine Agency) CHMP (Committee for Medicinal Products for Human Use), for the first-line maintenance ...

Read More >>
Belite Bio’s IND for LBS-008 gets FDA approval for Phase 1 trial
  Author: Mateen Dalal

Drug development company, Belite Bio’s Investigational New Drug application for LBS-008 (BPN-14967), developed to treat AMD and Stargardt disease, has reportedly been approved by the U.S. Food and Drug Administra...

Read More >>
Innovent doses first patient in bispecific antibody clinical trial
  Author: Pankaj Singh

Innovent Biologics, Inc., a top-notch biopharmaceutical firm which produces and commercializes superior quality medications, has recently declared that the first patient has successfully been dosed in China in the Phas...

Read More >>
Cortexyme launches GAIN Trail to study COR388’s effects on Alzheimer s
  Author: Mateen Dalal

Cortexyme, Inc. has reportedly launched the GAIN Trial, a worldwide Phase 2/3 clinical trial of COR388, the company’s lead investigational drug, in patients suffering from mild to moderate Alzheimer’s disea...

Read More >>
Quanta’s SC+ HFT results published in Hemodialysis International
  Author: Mateen Dalal

The results from the SC+ HFT with patients as well as healthcare professionals prove that SC+ is easy to use even with a significant learning decay period and minimal training. ...

Read More >>
Otonomy begins OTO-313 Phase 1/2 clinical study for tinnitus patients
  Author: Mateen Dalal

Results from the trial are expected in the first half of 2020 and the information would be used to design and plan any further clinical development Biopharmaceutica...

Read More >>
Regeneron Alnylam collaborate on a $1bn eye & CNS R&D agreement
  Author: Pankaj Singh

Regeneron Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have reportedly entered into a definitive collaborative deal. Authentic sources claim that the deal has been inked in a major effort to discover, advance ...

Read More >>
I-Mab and Jiangsu Nhwa collaborate with Biodextris and Ann Romney CND
  Author: Mateen Dalal

The strategic partnership is aimed at jointly developing a new immuno-stimulatory therapy for certain neurologic disorders. I-Mab Biopharma, a Shanghai-based biotec...

Read More >>
Grow Biotech, IPS Specials join forces to offer medicinal cannabis
  Author: Mateen Dalal

A joint venture will combine IPS Specials’ abilities as a licensed pharma importer with medical cannabis expertise of Grow Biotech Reports confirm that IPS Sp...

Read More >>
Innate Pharma features innovative cancer immunotherapies at AACR 2019
  Author: Mateen Dalal

New data describes that a combination of Innate’s anti-CD39 monoclonal antibody and ATP-inducing oxaliplatin had enhanced the control of tumor growth Innate P...

Read More >>
FDA’s new mammography proposal to help enhance diagnosis accuracy
  Author: Mateen Dalal

The FDA (Food & Drug Administration) has reportedly proposed a new rule that would require mammography providers to inform female patients with dense breast tissue about the fact that the condition may impact the a...

Read More >>
Teladoc Health announces acquisition of France-based MedecinDirect
  Author: Pankaj Singh

The deal is expected to be closed in first half of this year   Financial terms of the deal were not disclosed yet ...

Read More >>
Aerie Pharmaceuticals commences Phase 2 clinical trial of AR-1105
  Author: Mateen Dalal

AR-1105 is an intravitreal, fully bio-erodible PRINT-manufactured implant that releases steroid dexamethasone. Aerie Pharmaceuticals, an ophthalmic pharmaceutical c...

Read More >>
Merck’s KEYTRUDA ® wins EC approval for treatment of NSCLC patients
  Author: Mateen Dalal

KEYTRUDA® combination significantly improved overall survival in adults with metastatic squamous NSCLC   Its safety in combination ...

Read More >>
FDA approves new generic valsartan to reduce the shortage of drug
  Author: Pankaj Singh

The regulator reviewed the manufacturing and testing practices of India-based Alkem Laboratories Limited and found no traces of impurity The United States Food and ...

Read More >>
Akili & Shionogi partnership to bring new digital therapeutics to Asia
  Author: Pankaj Singh

The new strategic partnership would see the two enterprises collaborate on the development & commercialization of digital therapeutics in crucial Asian markets.   ...

Read More >>
Almac Group unveils Almac One solution for clinical trial supply chain
  Author: Mateen Dalal

Almac One™ would help sponsors to face the challenges existing in the drug development market It provide a single set of process to sponsors and enabl...

Read More >>
GE Healthcare and Adventist sign performance enhancement collaboration
  Author: Mateen Dalal

The five-year collaboration is expected to bring about financial improvement amounting to almost $100 million. GE Healthcare and Adventist Health, two of the most r...

Read More >>
BioXcel adds Pfizer, Merck to pancreatic cancer therapy collaboration
  Author: Mateen Dalal

BioXcel Therapeutics, Inc. has made an announcement confirming the addition of Germany-based Merck KGaA as well as Pfizer Inc. to its clinical collaboration with Nektar Therapeutics for evaluating an innovative triple ...

Read More >>
Novartis data confirms rapid response of Cosentyx® in China study
  Author: Mateen Dalal

The study proves to offer clear or almost clear skin in 8/10 patients within 16 weeks of Cosentyx® 300mg treatment. Swiss pharmaceutical major, Novartis AG (NVS...

Read More >>
Verrica announces positive results for molluscum contagiosum treatment
  Author: Mateen Dalal

The treatment would help to address unmet medical needs against serious skin lesions Reports suggest that the lead candidate of Verrica Pharmaceuticals, a drug-devi...

Read More >>
Hua Medicine confirms patient enrollment for study of diabetes drug
  Author: Mateen Dalal

Shanghai-based drug development firm Hua Medicine, which focuses on developing global first-in-class oral drug for treating Type 2 diabetes, has recently announced that it has completed patient enrollment for a Phase I...

Read More >>
Atara Biotherapeutics to present clinical results of Car T platform
  Author: Pankaj Singh

The firm is looking forward to its MSK collaborators’ clinical outcomes of a mesothelin-targeted autologous CAR T for patients suffering from advanced malignant pleural ailment &nbs...

Read More >>
GNA & Boehringer collaborate on ASF diagnostic test development
  Author: Pankaj Singh

Both the companies will come up with holistic solutions for farmers, veterinarians, and the food producing industry. The partnership aims to develop a ...

Read More >>
Sarepta to buy Myonexus to expand muscular dystrophy therapy portfolio
  Author: Mateen Dalal

Sarepta Therapeutics has recently confirmed that it is planning to acquire Myonexus Therapeutics in a $165 million deal, by exercising a purchase option that was part of a gene therapy partnership commenced by the firm...

Read More >>
Scholar Rock’s Phase 1 study of SRK-015 delivers positive interim data
  Author: Mateen Dalal

Scholar Rock Holding Corporation, the clinical-stage biopharma company focusing on treating serious diseases which are affected by protein growth factors, has recently confirmed positive interim results for its Phase 1...

Read More >>
Ocutrx develops advanced Oculenz AR glasses with eye-tracking ability
  Author: Mateen Dalal

California-based augmented reality (AR) glasses manufacturer, Ocutrx Vision Technologies, LLC, has recently unveiled its new, cutting-edge design for Oculenz™ AR Wear glasses, which is the company’s flagshi...

Read More >>
Morphic to collaborate with Janssen to develop integrin therapeutics
  Author: Mateen Dalal

Morphic has attained leadership position in the development of oral integrin inhibitors with the help of the ground-breaking structural research Morphic Therapeutic...

Read More >>
AzurRx doses first patients in Phase II OPTION study for EPI therapy
  Author: Mateen Dalal

AzurRx BioPharma, Inc. has recently informed that the company has dosed the first patients in its Phase II OPTION clinical study aimed at investigating MS1819-SD in cystic fibrosis (CF) patients who experience exocrine...

Read More >>
Indivior introduces generic version of its Suboxone opioid drug
  Author: Pankaj Singh

The company said its launch of an authorize generic version of the drug would prompt other firms to introduce their own cheaper versions The announ...

Read More >>
Philippines FDA bans Sanofis dengue vaccine due to compliance issue
  Author: Mateen Dalal

Reports confirm that the Philippines has revoked the product license for Dengvaxia, the dengue vaccine from Sanofi, after the France-based pharmaceutical company failed to comply with directives of regulators. Apparently...

Read More >>
CASI Pharma gets NMPA’s nod to conduct confirmatory trial of ZEVALIN®
  Author: Mateen Dalal

The firm previously secured greater China rights to ZEVALIN® from Spectrum and aims to launch ZEVALIN® in the country. CASI Pharmaceutical...

Read More >>
Inventiva declares results of Phase IIb clinical trial of lanifibranor
  Author: Mateen Dalal

The FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48 The French clinical-stage biopharmaceutical firm Inv...

Read More >>
Merck presents data from new Phase 3 trials to treat mCRPC patients
  Author: Mateen Dalal

Pharmaceutical major Merck & Co Inc., has apparently announced the launch of three late-stage studies for KEYTRUDA – its cancer immunotherapy. Trusted reports cite that these studies are being introduced as a...

Read More >>
Life science firm Jubilant & Sanofi collaborate on CNS therapeutics
  Author: Mateen Dalal

Jubilant will deliver Sanofi drug discovery services with its integrated drug discovery platform. The Bengaluru-based arm of the reputed Jubilant Life Sciences, Jub...

Read More >>